Skip to content
DataLookout
Menu

OPPO-WATCHNCT07912671

Out-Patient Proactive Observation With Wearable-Assisted Tracking for Cardiovascular Health Management

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Life's Essential 8 (LE8) Cardiovascular Health Score
Timeframe: From baseline through 12 months

Secondary (40)

Change in Life's Essential 8 (LE8) Blood Lipids Component Score
Change in Life's Essential 8 (LE8) Blood Glucose Component Score
Change in Life's Essential 8 (LE8) Blood Pressure Component Score
Change in Life's Essential 8 (LE8) Body Mass Index Component Score
Change in Life's Essential 8 (LE8) Physical Activity Component Score
Show 35 moreShow less
Change in Life's Essential 8 (LE8) Sleep Duration Component Score
Change in Life's Essential 8 (LE8) Nicotine Exposure Component Score
Change in Life's Essential 8 (LE8) Diet Component Score
LE8 Score ≥80 points
Proportion of Participants With an Increase of ≥5 Points in the Life's Essential 8 (LE8) Cardiovascular Health Score at 12 Months
Proportion of Participants With an Increase of ≥10 Points in the Life's Essential 8 (LE8) Cardiovascular Health Score at 12 Months
Proportion of Participants With an Increase of ≥15 Points in the Life's Essential 8 (LE8) Cardiovascular Health Score at 12 Months
Major Adverse Cardiovascular Events (MACE)
Cardiac death
Acute myocardial infarction
Hospitalization for heart failure
Coronary revascularization
Incidence of New-onset Diabetes Mellitus
Incidence of New-onset Hypertension
Daytime Average Heart Rate
Nighttime Average Heart Rate
24-hour Average Heart Rate
Proportion of Participants Achieving Target Resting Heart Rate at 12 Months
Heart Rate Deceleration Capacity (DC)
Heart Rate Acceleration Capacity (AC)
Arrhythmia and Electrophysiological Parameters
Incidence of New-onset Atrial Fibrillation
Atrial Fibrillation Burden
Low-Density Lipoprotein Cholesterol (LDL-C)
Glycated Hemoglobin (HbA1c)
Fasting Blood Glucose (FBG)
Uric Acid (UA)
Homocysteine (HCY)
Changes in Cardiovascular Medication Use
Medication Adherence
Change in EQ-5D-5L Index Value
Change in EQ Visual Analogue Scale (EQ VAS) Score
Patient Health Questionnaire-9 (PHQ-9) Score
Blood Pressure Control Rate
Change in Peripheral Oxygen Saturation (SpO₂)

Arms and interventions

Wearable Device-Based Management GroupExperimental

Participants receive wearable device-based, LE8-guided management with access to their monitoring data, health and medication reminders, and individualized LE8 score feedback, together with routine in-person cardiology outpatient follow-up every three months for 12 months.

Data-Blinded Wearable Monitoring GroupActive comparator

Participants wear a smartwatch for data collection but do not have access to monitoring data, health or medication reminders, or Life's Essential 8 (LE8) score feedback. They receive routine in-person cardiology outpatient follow-up every three months for 12 months.

Devices: Wearable Device-Based Monitoring and LE8 Feedback

Other: Routine Outpatient Care With Data-Blinded Wearable Monitoring

Sites

1 site in 1 country

  • Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China